SynCardia to Honor Eight Leading Total Artificial Heart Hospitals during ISHLT
This year’s awards recognize leadership in the Destination Therapy clinical trial, pioneering use of the 50cc Total Artificial Heart, outstanding outcomes, implant milestones and best launch.
March 29, 2017 – During the 37th annual meeting of the International Society for Heart & Lung Transplantation (ISHLT)* being held April 5-8 in San Diego, SynCardia Systems, LLC will honor the following eight hospitals for their lifesaving use of the SynCardia temporary Total Artificial Heart (TAH-t):
- Destination Therapy Leader
Virginia Commonwealth University (VCU) Medical Center
VCU Medical Center is the leading investigational site in the FDA-approved Investigational Device Exemption clinical trial of the 70cc Total Artificial Heart for destination therapy.
- Pioneer Award – U.S.
Ann & Robert H. Lurie Children’s Hospital of Chicago
Jaheim Whigham, 11, became the smallest and youngest patient to receive the 50cc Total Artificial Heart in the U.S. when Lurie Children’s performed its first implant in December 2016.
- Pioneer Award – International
Royal Brompton & Harefield NHS Foundation Trust
London, United Kingdom
Thanks to extraordinary cooperation between these two institutions, the smallest patient to receive the 50cc Total Artificial Heart in Europe was successfully bridged to transplant.
- Outstanding Outcomes – U.S.
University of Michigan Frankel Cardiovascular Center
Ann Arbor, MI
Eighty percent of patients who received the SynCardia Total Artificial Heart at Frankel Cardiovascular Center were bridged to transplant or are currently at home on support.
- Outstanding Outcomes – International
Montreal Heart Institute
Eighty percent of patients who received the SynCardia Total Artificial Heart at Montreal Heart Institute were bridged to transplant.
- Best Launch Award
Tampa General Hospital (TGH)
TGH completed certification to implant the Total Artificial Heart in only 82 days and performed three implants during its first year as a SynCardia Certified Center.
- Milestone Award – 175+ implants
Heart and Diabetes Center NRW
Bad Oeynhausen, Germany
- Milestone Award – 100+ implants
VCU Medical Center
- Milestone Award – 25 implants
University of Washington Medical Center
Attending ISHLT? Visit SynCardia at Booth 216 in the Harbor Ballroom at the Manchester Grand Hyatt San Diego.
*Awards are not part of the official ISHLT program
CAUTION – In the United States, the use of the SynCardia 70cc TAH-t for destination therapy is investigational.
CAUTION – In the United States, the 50cc SynCardia temporary Total Artificial Heart is an investigational device, limited by federal law to investigational use.
About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.
Janelle Drumwright, email@example.com, (520) 547-7463